LIVE POLIO IRUS VACCINES

380
Efficacy-Laboratory Evidence
100-
w
90
CI)
80-
0) 70-
O
a- 60
0 50
40
wI-
Z
2
30
u 20
Iii 10
7-11 MONTHS (50)
PRE-NONE TRIPLE POSITIVE
/ \"-NON POLIO t POLIO
//-:::-10 ONLY
-100-
- 90-
I YEAR (47) 2 YEARS (26)
PRE-19% TRIPLE POSITIVE rlOO0 PRE-62% TRIPLE POSITIVE
- 80- 1 -. \
-70 9
"- ,
- 60
50
-40
-30
-20
I0 : .
2 PRE 1 2 3 4 6 8
-90 -
80 -
70 -
60;
-50 -
-40
- 30
20
/ *1
PRE ¡ 2 3 4 6 8 12
3 YEARS (35)
4 YEARS (34)
100- PRE- 79% TRIPLE POSITIVE -100- PRE-
W
91% TRIPLE POSITIVE
90- - 90
80- - 80
O
F-
z
0O
Iri
Q. Li
o-
70- r _ 70-
60- / - 60 x
50Y 50¡ -
40 40
30 30
20- 20
0 2
2 3 4 6 8
PRE I 2 3 4 6 8 12 PRE I 2 3 4 6 8
100
90
80
70O
60
5-10 Yrs. Inclusive (82)
PRE- 86 % TRIPLE POSITIVE
40 -//E : /^\4
40
30
20 - .
2 PRE 1 2 3 4 6 8 12
FIc. 3.
Polioviruses and other enteric viruses in Group of 274 children tested just before and at
weekly intervals after single dose of trivalent oral poliovirus vaccine.
Toluca, Mexico-Aug. to Nov. '59.
'. 50-
NP
. 4
o 30 i
>d 20-
Anib 57%
%o i - 30%
Posit¡ive II 43%
83% 75% 96% 94%
83% 79% 100% 85%
77% 79% 88% 88%
97% 97% 100% 91% 100%
97% 100% 100% 87% 100%
91% 94% 100% 96% 96%
FIG. 4. Incidence of various types of poliovirus and of other enteric viruses (NP) in 1 to 5 year old
children randomly selected just before and at indicated monthly intervals after single dose of trivalent
oral poliovirus vaccine.
Toluca, Mexico-Aug. to Nov. '59.